Investor Overview

Corporate Profile

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule, oligomer antagonists for age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate zervimesine (also known as CT1812) in clinical programs in Alzheimer’s disease and dementia with Lewy bodies (DLB).

Read a letter from our CEO
View Stock Information
Corporate
Corporate Presentation (PDF)

Press Releases

July 10, 2025
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
July 1, 2025
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
June 25, 2025
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
View All Press Releases

Events

July 27, 2025
Alzheimer’s Association International Congress 2025
May 4, 2025 - May 8, 2025
Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual meeting
April 1, 2025 - April 4, 2025
AD/PD™ 2025 Alzheimer’s & Parkinson’s Diseases Conference
March 20, 2025
Fourth Quarter and Full Year 2024 Financial Results Conference Call
View All Events

SEC Filings

View All SEC Filings

Investor Relations Contact

Cognition Therapeutics
info@cogrx.com

Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Email Alerts

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org